Clinical Trial

Risk Stratification and Treatment Decisions in Infantile Hemangioma With Minimal or Arrested Growth

Study acronym: IH-MAGRST
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Infantile hemangioma with minimal or arrested growth (IH-MAG) is a subtype of infantile hemangioma that shows little or no obvious growth during infancy. Although these lesions may appear less active than classic infantile hemangiomas, some may still be associated with ulceration, functional risk, permanent disfigurement, or structural anomalies. This prospective observational cohort study will compare infants with IH-MAG and infants with classic infantile hemangioma at their first specialist evaluation. Each participant will undergo routine clinical assessment, standardized photography, risk classification according to the 2019 American Academy of Pediatrics guideline, and Hemangioma Severity Scale scoring. The main outcome is the initial management recommendation after specialist assessment, categorized as active management or treatment versus observation. The study will not assign any treatment. All management recommendations will be made by clinicians according to routine clinical practice and guideline-based assessment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-06-21.
Trial Details
NCT Number NCT07669545
Lead Sponsor West China Hospital
Conditions Infantile Hemangioma (IH)
Enrollment 150 participants
Start Date 2026-06-20
Primary Completion 2027-12-30 (estimated)
Study Completion 2028-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02